Clark Estates Inc. NY Has $3.12 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clark Estates Inc. NY trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,874 shares of the medical equipment provider’s stock after selling 4,226 shares during the quarter. Clark Estates Inc. NY owned about 0.05% of Lantheus worth $3,120,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Victory Capital Management Inc. increased its holdings in shares of Lantheus by 13.4% during the 4th quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider’s stock valued at $7,795,000 after acquiring an additional 10,297 shares during the last quarter. Keybank National Association OH bought a new stake in Lantheus during the fourth quarter worth approximately $27,526,000. Torray Investment Partners LLC grew its holdings in Lantheus by 17.0% during the fourth quarter. Torray Investment Partners LLC now owns 19,166 shares of the medical equipment provider’s stock valued at $1,715,000 after purchasing an additional 2,788 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Lantheus by 108.3% in the fourth quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider’s stock valued at $203,000 after purchasing an additional 1,182 shares during the period. Finally, Bridges Investment Management Inc. lifted its stake in shares of Lantheus by 98.9% in the fourth quarter. Bridges Investment Management Inc. now owns 12,070 shares of the medical equipment provider’s stock worth $1,080,000 after buying an additional 6,001 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Up 3.5 %

Shares of LNTH stock opened at $98.17 on Wednesday. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89. The company has a market capitalization of $6.72 billion, a P/E ratio of 16.33 and a beta of 0.44. The stock has a 50 day moving average of $89.97 and a two-hundred day moving average of $96.73.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on LNTH. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Insider Activity

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.